Wells Fargo
NTLA icon

Wells Fargo’s Intellia Therapeutics NTLA Stock Holding History

Wells Fargo’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,600
Closed -$1.71M – 7626
2022
Q3 		$1.71M Buy
+30,600
New +$1.9M ﹤0.01% 2853

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo's NTLA Position: Q1 2026 in Review

Wells Fargo reduced its Intellia Therapeutics (NTLA) stake by 23% in Q1 2026, selling an estimated $1.27M and leaving 333,897 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2725.

Wells Fargo first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $18.6M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Wells Fargo held 333,897 shares of Intellia Therapeutics worth $4.28M as of Q1 2026.
  • Wells Fargo sold 99,845 Intellia Therapeutics shares in Q1 2026, an estimated $1.27M.
  • Intellia Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2725 holding.
  • Wells Fargo first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • Wells Fargo's Intellia Therapeutics position peaked at $18.6M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.